TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3451888

Group type: EXPERIMENTAL
Intervention: 100 mg falipamil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low doses of atropine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1 mg cumulative dose of atropine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 mg falipamil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ULFS 49 Cl (3 different oral doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 X 2.5 mg p.o. (minimal effective dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 X 5 mg p.o. (therapeutic dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: falipamil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ULFS 49 Cl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Side-effects typical for 'specific bradycardic agents'
Number of subjects: 0
Study: 29374674

Group type: EXPERIMENTAL
Intervention: Text message intervention providing information, motivation, and support for medication adherence, smoking cessation, healthy diet, and exercise.
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Text message intervention
Number of subjects: 1400
Study: 28376651

Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03%
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: brinzolamide 1.0%/timolol maleate 0.5% fixed combination (BTFC)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (healthy eyes)
Number of subjects: 67
Study: 26252845

Group type: EXPERIMENTAL
Intervention: Stent insertion
Number of subjects: 52

Group type: COMPARATOR
Intervention: Surgical decompression
Number of subjects: 52
Study: 23232154

Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg, max 600 mg) and Codeine (1 mg/kg, max 60 mg)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Ibuprofen (10 mg/kg, max 600 mg) and Placebo
Number of subjects: 81
Study: 21645639

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 40
Study: 20108849

Group type: EXPERIMENTAL
Intervention: 6-week neuromuscular-training program including plyometric, functional-strengthening, balance, and stability-ball exercises
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 6-week neuromuscular-training program
Number of subjects: 62
Study: 17046324

Group type: EXPERIMENTAL
Intervention: Methionine loading
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 12772727

Group type: EXPERIMENTAL
Intervention: BCR of 7.9 mm
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: BCR of 8.3 mm
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: BCR of 8.7 mm
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Asian eyes
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Non-Asian eyes with steep BCR
Number of subjects: 114
Study: 10702174

Group type: EXPERIMENTAL
Intervention: 20 mg Zn/d
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: 20 mg Fe/d
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: 20 mg Zn/d plus 20 mg Fe/d
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 9316954

Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Number of subjects: 31

Group type: COMPARATOR
Intervention: Allogeneic blood transfusion
Number of subjects: 31
Study: 8404191

Group type: COMPARATOR
Intervention: SHRZ/HR regimen (2 months of daily streptomycin, isoniazid, rifampin, and pyrazinamide followed by 4 months of isoniazid plus rifampin)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: SHZ Cipro/H Cipro regimen (2 months of daily streptomycin, isoniazid, pyrazinamide, and ciprofloxacin followed by 4 months of isoniazid plus ciprofloxacin)
Number of subjects: 35
Study: 3435909

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg twice daily)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study: 28222574

Group type: EXPERIMENTAL
Intervention: Morning exercise (E: cycle ergometer 45 min, 50% VO2peak)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Evening exercise (E: cycle ergometer 45 min, 50% VO2peak)
Number of subjects: 13
Study: 27793237

Group type: EXPERIMENTAL
Intervention: Sufentanil in combination with low-dose hyperbaric bupivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 24823692

Group type: EXPERIMENTAL
Intervention: Spouse's functional limitations
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Personal resources
Number of subjects: 6
Study: 22162570

Group type: EXPERIMENTAL
Intervention: Infusional fluorouracil, leucovorin, and oxaliplatin
Number of subjects: 364

Group type: COMPARATOR
Intervention: Irinotecan, leucovorin, and fluorouracil
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: pcCRC
Number of subjects: 364
Study: 20423964

Group type: EXPERIMENTAL
Intervention: Primary HPV DNA test (hybrid capture II) with cytology triage if the result was positive
Number of subjects: 58076

Group type: COMPARATOR
Intervention: Conventional cytological screening (reference)
Number of subjects: 58076

Group type: EXPERIMENTAL
Intervention: HPV arm
Number of subjects: 58076

Group type: EXPERIMENTAL
Intervention: Normal or negative test result in HPV arm
Number of subjects: 58076
Study: 17898705

Group type: EXPERIMENTAL
Intervention: Saquinavir/ritonavir with omeprazole simultaneously
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Saquinavir/ritonavir with omeprazole 2 h apart
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saquinavir/ritonavir without omeprazole
Number of subjects: 12
Study: 16860169

Group type: EXPERIMENTAL
Intervention: ASA 325 mg/d for 1 week, followed by ASA 100 mg/d plus clopidogrel 300 mg loading dose followed by 100 mg/d for 36 weeks (ASA+Clop group)
Number of subjects: 86

Group type: COMPARATOR
Intervention: ASA alone (325 mg/d for 1 week, followed by 75 mg/d for 36 weeks) (ASA group)
Number of subjects: 86
Study: 12623974

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/day, given 8 hours after awakening (time 2)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/day, given before bedtime (time 3)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Placebo given at bedtime
Number of subjects: 341
Study: 10840491

Group type: EXPERIMENTAL
Intervention: Automatic external defibrillators (AEDs)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 6
Study: 9337682

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 79
Study: 8408538

Group type: EXPERIMENTAL
Intervention: Counselling intervention (three sessions of counselling before, during, and after the first treatment cycle)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (information about the treatment programme only)
Number of subjects: 0
Study: 3547370

Group type: EXPERIMENTAL
Intervention: Paravertebral bupivacaine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Epidural morphine (Control)
Number of subjects: 26
Study: 31219517

Group type: EXPERIMENTAL
Intervention: mECX+L (modified ECX plus lapatinib)
Number of subjects: 46

Group type: COMPARATOR
Intervention: sECX (standard ECX)
Number of subjects: 46
Study: 28968877

Group type: EXPERIMENTAL
Intervention: School-based and village-wide preventive chemotherapy strategies (MDA) for Schistosoma mansoni
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mass drug administration (MDA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDA strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predictive analysis from prior year data
Number of subjects: 0
Study: 25148380

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 79
Study: 23405376

Group type: EXPERIMENTAL
Intervention: Self-administered testing using the Gen-Probe APTIMA Combo 2 (AC2) kit
Number of subjects: 374
Study: 21884958

Group type: EXPERIMENTAL
Intervention: Renal Denervation (RD)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 46
Study: 19706084

Group type: EXPERIMENTAL
Intervention: 1.2% clindamycin and 0.025% tretinoin (CLIN/RA) gel
Number of subjects: 1710

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 1710

Group type: COMPARATOR
Intervention: 1.2% clindamycin (CLIN)
Number of subjects: 1710

Group type: COMPARATOR
Intervention: 0.025% tretinoin (RA)
Number of subjects: 1710
Study: 16730066

Group type: EXPERIMENTAL
Intervention: 5‐mg intralesional injection of 5‐FU weekly for 2 weeks
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 20‐mg intralesional injection of triamcinolone
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (topical steroid alone)
Number of subjects: 109
Study: 15249533

Group type: EXPERIMENTAL
Intervention: PACE programme
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: PACE training and intervention materials
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Counselling implementation
Number of subjects: 29
Study: 11744967

Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide 5 mg/ml injection
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Simple incision and curettage
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Incision, curettage and intralesional triamcinolone acetonide injection
Number of subjects: 26
Study: 9269010

Group type: EXPERIMENTAL
Intervention: 0.25 mg sublingual triazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.25 mg oral triazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8329825

Group type: EXPERIMENTAL
Intervention: Intravenous GHRH(1-29)-NH2 at 0.25 microgram/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous GHRH(1-29)-NH2 at 1-2 micrograms/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intranasal GHRH(1-29)-NH2 at 50 micrograms/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Repeated intranasal GHRH(1-29)-NH2 administration
Number of subjects: 30
Study: 3526610

Group type: EXPERIMENTAL
Intervention: NG suction (Group I)
Number of subjects: 60
Study: 30612537

Group type: EXPERIMENTAL
Intervention: MRI-based selection for EVT
Number of subjects: 1265

Group type: COMPARATOR
Intervention: CTA-based selection for EVT
Number of subjects: 1265
Study: 27779907

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study: 25265874

Group type: EXPERIMENTAL
Intervention: Remotely transmitted touch
Number of subjects: 0
Study: 22692119

Group type: EXPERIMENTAL
Intervention: o‐uchi‐gari protocol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oxygen consumption
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: total energy expenditure per repetition
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: training protocols
Number of subjects: 10
Study: 21742946

Group type: EXPERIMENTAL
Intervention: High-soy diet (2 servings of soy milk, tofu, or soy nuts, ∼50 mg of isoflavones per day)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Low-soy diet (usual diet)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: High-soy diet
Number of subjects: 96
Study: 19356389

Group type: EXPERIMENTAL
Intervention: Roflumilast 500 microg once daily (Days 1 and 15) + Erythromycin 500 mg three times daily (Days 9 - 21)
Number of subjects: 16
Study: 16485755

Group type: EXPERIMENTAL
Intervention: Wavelet coherence
Number of subjects: 26

Group type: COMPARATOR
Intervention: Fourier coherence
Number of subjects: 26
Study: 12956481

Group type: EXPERIMENTAL
Intervention: Biostite
Number of subjects: 96

Group type: COMPARATOR
Intervention: No defect fill (Control)
Number of subjects: 96
Study: 10903014

Group type: COMPARATOR
Intervention: Intra-articular NSAIDs
Number of subjects: 844

Group type: COMPARATOR
Intervention: IVRA NSAIDs
Number of subjects: 844

Group type: COMPARATOR
Intervention: Intrawound NSAIDs
Number of subjects: 844

Group type: COMPARATOR
Intervention: Local infiltration with NSAIDs
Number of subjects: 844
Study: 8955540

Group type: EXPERIMENTAL
Intervention: Schwab‐Gilleard Depression Scale (SGDS)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Geriatric Depression Scale (GDS)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Short‐Comprehensive Assessment and Referral Evaluation (CARE)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Clifton Assessment Procedures for the Elderly (CAPE)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Schwab‐Gilleard Depression Scale (SGDS) and CARE (14 months previously)
Number of subjects: 166
Study: 1519573

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (40 mg/day for 4 weeks)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (for 4 weeks)
Number of subjects: 13
Study: 6470191

Group type: EXPERIMENTAL
Intervention: Lithium treatment in 21 children
Number of subjects: 61
Study: 30819485

Group type: EXPERIMENTAL
Intervention: Transradial access (TRA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Transfemoral access (TFA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of TRA and TFA
Number of subjects: 30
Study: 29710676

Group type: EXPERIMENTAL
Intervention: PRP + MP group
Number of subjects: 115

Group type: COMPARATOR
Intervention: PRP group
Number of subjects: 115

Group type: COMPARATOR
Intervention: MP group
Number of subjects: 115
Study: 25969346

Group type: EXPERIMENTAL
Intervention: Chest compressions after a night shift
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control day chest compressions
Number of subjects: 67
Study: 24262813

Group type: EXPERIMENTAL
Intervention: 50mg D-cycloserine administered after each of ten CBT sessions
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo administered after each of ten CBT sessions
Number of subjects: 27
Study: 22724029

Group type: EXPERIMENTAL
Intervention: Paromomycin (PM) 20 mg/kg/day for 21 days
Number of subjects: 205

Group type: COMPARATOR
Intervention: Sodium stibogluconate (SSG) 20 mg/kg/day for 30 days
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Combination of PM (15 mg/kg/day) and SSG (20 mg/kg/day) for 17 days
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: End of treatment efficacy for PM
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: End of treatment efficacy for SSG & PM
Number of subjects: 205
Study: 20471234

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone (BDP)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combined treatment of BDP plus montelukast (ML)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 18605812

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 1275

Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 1275
Study: 16260434

Group type: EXPERIMENTAL
Intervention: Surviving Cancer Competently Intervention Program‐Newly Diagnosed (SCCIP‐ND)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 19
Study: 12499890

Group type: EXPERIMENTAL
Intervention: ELAD therapy
Number of subjects: 5
Study: 10567271

Group type: EXPERIMENTAL
Intervention: Stentless aortic valve (SAV)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Conventional stented bioprosthesis (CSB)
Number of subjects: 180
Study: 8915668

Group type: EXPERIMENTAL
Intervention: Idarubicin 8 mg/m2/day for 5 days
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Rubidazone 200 mg/m2/day for 4 days
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: High dose ARA-C plus m-Amsa
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT)
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Intensive consolidation chemotherapy (ICC)
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Autologous unpurged bone marrow transplantation (ABMT)
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: GM-CSF 5 micrograms/kg/day
Number of subjects: 786

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 786
Study: 1670621

Group type: EXPERIMENTAL
Intervention: Lymecycline treatment for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6882615

Group type: EXPERIMENTAL
Intervention: Lipid preparation (Diazemuls)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Aqueous preparation (Valium)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 100
Study: 30963440

Group type: EXPERIMENTAL
Intervention: Lifestyle Improvement through Food and Exercise (LIFE), a culturally tailored, 28-session community-based intervention focused on diet and physical activity
Number of subjects: 211

Group type: COMPARATOR
Intervention: Standard of care comparison group receiving two group DSME classes
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Lifestyle Improvement through Food and Exercise (LIFE)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Standard of care comparison group
Number of subjects: 211
Study: 29568979

Group type: EXPERIMENTAL
Intervention: Catheter-over-needle (Contiplex C™)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Catheter-through-needle (Contiplex Touhy™)
Number of subjects: 40
Study: 27483064

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg/d via daily subcutaneous injection for 180 days)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 300
Study: 25197833

Group type: EXPERIMENTAL
Intervention: Renal dysfunction
Number of subjects: 4321

Group type: EXPERIMENTAL
Intervention: Renal dysfunction in hypoperfusion-dominant profiles
Number of subjects: 4321

Group type: EXPERIMENTAL
Intervention: Renal dysfunction in congestion-dominant profiles
Number of subjects: 4321
Study: 22892437

Group type: EXPERIMENTAL
Intervention: Low glycemic load (GL) diet
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Low glycemic load (GL) test breakfast
Number of subjects: 84
Study: 19604249

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 25

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 25
Study: 17470860

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Number of subjects: 244

Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 244
Study: 15175566

Group type: EXPERIMENTAL
Intervention: Intra-arterial vitamin C (25 mg/min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral vitamin C (1 g daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 8
Study: 10838017

Group type: EXPERIMENTAL
Intervention: Ivabradine (multiple dose oral administration every 12 h, eight active dosing levels)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 78
Study: 9327310

Group type: EXPERIMENTAL
Intervention: Forced-air warming devices
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual patient care (warm blankets and overhead heat lamps)
Number of subjects: 60
Study: 8261939

Group type: COMPARATOR
Intervention: Garcinia Kola (15 grammes per subject)
Number of subjects: 19
Study: 3766413

Group type: EXPERIMENTAL
Intervention: Isosorbide 5‐mononitrate (IS 5‐MN), 40 mg twice daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3399285

Group type: EXPERIMENTAL
Intervention: High dose intravenous gamma-globulin (0.6 g/kg every 4 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dose intravenous gamma-globulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low dose therapy (not specified in detail)
Number of subjects: 0
Study: 31971616

Group type: EXPERIMENTAL
Intervention: Sutured closure of the fascial defect before intraperitoneal onlay mesh (IPOM) repair
Number of subjects: 80

Group type: COMPARATOR
Intervention: No closure of the fascial defect before intraperitoneal onlay mesh (IPOM) repair
Number of subjects: 80
Study: 31642434

Group type: EXPERIMENTAL
Intervention: Calorie-enriched formula milk powder (100 kcal/100 mL)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Normal calorie formula milk powder (67 kcal/100 mL)
Number of subjects: 43
Study: 28619777

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate disc (CHG)
Number of subjects: 1240

Group type: EXPERIMENTAL
Intervention: Integrated securement dressing (ISD)
Number of subjects: 1240

Group type: COMPARATOR
Intervention: Securement device (SED)
Number of subjects: 1240

Group type: COMPARATOR
Intervention: No disc (control for dressing hypothesis)
Number of subjects: 1240
Study: 25649018

Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 175
Study: 24009294

Group type: EXPERIMENTAL
Intervention: Spironolactone (SPR) added to ARB
Number of subjects: 136

Group type: COMPARATOR
Intervention: ACE inhibitors and ARBs (continuation regimen)
Number of subjects: 136
Study: 21782524

Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 17851675

Group type: EXPERIMENTAL
Intervention: Tensor veli palatini muscle function analysis using electromyography (EMG)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 24
Study: 16960401

Group type: EXPERIMENTAL
Intervention: Recombinant human TSH (rhTSH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional TSH stimulation (hypothyroidism induction)
Number of subjects: 0
Study: 14761120

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (160 mJ/pulse, 10 Hz) plus enamel matrix protein derivative (EMD)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) with hand instruments plus EDTA and EMD
Number of subjects: 22
Study: 10708085

Group type: EXPERIMENTAL
Intervention: Posterior capsulorrhaphy (group 1, 96 cases)
Number of subjects: 180

Group type: COMPARATOR
Intervention: No posterior capsulorrhaphy (group 2, 84 cases)
Number of subjects: 180
Study: 9575601

Group type: EXPERIMENTAL
Intervention: Picotamide, 300 mg t.i.d.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 7902022

Group type: EXPERIMENTAL
Intervention: Levocabastine
Number of subjects: 95

Group type: COMPARATOR
Intervention: Sodium cromoglycate
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 3709210

Group type: EXPERIMENTAL
Intervention: Topical 2% fenticonazole cream
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical 2% miconazole cream
Number of subjects: 60
Study: 30477828

Group type: EXPERIMENTAL
Intervention: Reminiscence therapy applied through individual sessions for 8 weeks, with house visits once a week.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no intervention mentioned).
Number of subjects: 50